Long-term follow-up: AML17 trial of ATO and ATRA vs the standard of care in APL
Alan Burnett • 2 Dec 2016
Highlights from ASH 2015 by Alan Burnett, MD on acute myeloid leukemia (AML)
Alan Burnett • 4 Dec 2015
Pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence
Klaus Metzeler • 9 Jun 2016
Acute leukemias discussion: what does genomics and epigenomics tell us about patient management?
Ari Melnick et al.
European LeukemiaNet 2017 AML recommendations: impact on risk stratification and survival
Challenging the norms for elderly AML treatment: clinical trials & intensive therapy
Alan Burnett et al. • 17 Feb 2018